Evidence map›Paper›PMID 23812558›Full record

ReviewJournal of lipid research2014

Cardioprotective functions of HDLs.

Kerry-Anne Rye, Philip J Barter

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of lipid research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03646019 (Serum Oxidative Status as a Potential Predictor of Coronary Artery Disease.), which is not on this map. Cited by 158 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03646019 unknown statusnot on this mapstarted 2018, after this paper: background citation

Serum Oxidative Status as a Potential Predictor of Coronary Artery Disease.

TypeobservationalSponsorProf. Tony hayek MDRan2018 to 2019Enrolled200ConditionsCoronary Artery Disease, Paraoxanase 1, Thiobarbituric Acid Reactive Substances, Thiol Groups
3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kerry-Anne RyeLipid Research Group, Centre for Vascular Research, University of New South Wales, Sydney, New South Wales, Australia 2052.
Philip J Barter

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple human population studies have established the concentration of high density lipoprotein (HDL) cholesterol as an independent, inverse predictor of the risk of having a cardiovascular event. Furthermore, HDLs have several well-documented functions with the potential to protect against cardiovascular disease. These include an ability to promote the efflux of cholesterol from macrophages in the artery wall, inhibit the oxidative modification of low density lipoproteins (LDLs), inhibit vascular inflammation, inhibit thrombosis, promote endothelial repair, promote angiogenesis, enhance endothelial function, improve diabetic control, and inhibit hematopoietic stem cell proliferation. There are undoubtedly other beneficial functions of HDLs yet to be identified. The HDL fraction in human plasma is heterogeneous, consisting of several subpopulations of particles of varying size, density, and composition. The functions of the different HDL subpopulations remain largely unknown. Given that therapies that increase the concentration of HDL cholesterol have varying effects on the levels of specific HDL subpopulations, it is of great importance to understand how distribution of different HDL subpopulations contribute to the potentially cardioprotective functions of this lipoprotein fraction. This review summarizes current understanding of the relationship of HDL subpopulations to their cardioprotective properties and highlights the gaps in current knowledge regarding this important aspect of HDL biology.

Indexed as

AnimalsCardiovascular DiseasesHumansLipoproteins, HDLRiskLipoproteins, HDLangiogenesisapoptosischolesterol effluxendothelial functionendothelial repairoxidationpancreatic beta cell functionthrombosisvascular inflammation

Identifiers

PMID23812558
PMCPMC3886656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.